Hydrocodone polymorphs
Hydrocodone bitartrate forms are disclosed which are useful as analgesic agents either in combination with or as replacements for hydrocodone bitartrate.
1. A form of hydrocodone bitartrate which is selected from the group consisting of: Form II, Form III, Form IV, Form V, Form VI, Form VII, Form VIII, Form IX, Form X, and an amorphous form; wherein
Form II has the following XRPD °2θ peaks and relative intensities (I/Io):
°2θ
I/Io
10.39
100
10.66
11
14.36
12
16.61
12
16.98
14
17.13
43
18.32
28
20.86
27
21.22
17
21.37
53
23.01
25
24.81
19
27.17
12
28.29
10
30.24
19
33.55
20
Form III has the following XRPD °2θ peaks and relative intensities:
°2θ
I/Io
4.86
14
6.74
10
8.82
21
9.10
13
9.40
19
10.40
100
13.44
22
14.16
23
14.61
12
16.30
45
16.64
24
16.96
35
17.48
19
18.91
10
19.94
60
20.33
40
21.78
20
22.24
10
22.60
16
23.57
51
23.96
12
24.41
14
25.38
18
26.74
35
27.42
34
27.68
17
29.51
10
30.87
19
31.54
10
36.40
11
Form IV has the following XRPD °2θ peaks and relative intensities:
°2θ
I/Io
7.54
22
11.21
66
12.09
16
15.24
57
15.66
24
17.87
16
19.21
49
19.98
19
21.74
11
22.80
100
23.54
18
24.58
26
25.02
27
Form V has the following XRPD °2θ peaks and relative intensities:
°2θ
I/Io
6.57
56
8.96
27
12.16
30
14.54
53
15.16
10
19.88
14
20.76
100
22.62
12
24.04
17
24.82
15
Form VI has the following XRPD °2θ peaks and relative intensities:
°2θ
I/Io
6.54
12
6.85
51
9.39
40
12.54
36
12.92
62
13.30
37
14.10
28
15.23
48
16.62
78
17.00
24
18.01
100
18.82
15
19.67
23
20.75
43
21.22
24
21.85
92
23.21
17
23.76
16
24.52
27
26.15
48
27.74
14
28.06
30
28.52
10
28.91
30
29.38
13
30.03
11
31.40
33
31.88
12
32.74
10
34.46
10
35.14
29
35.66
20
35.96
11
37.28
13
37.80
10
38.58
22
39.08
11
Form VII has the following XRPD °2θ peaks and relative intensities:
°2θ
I/Io
6.90
40
9.42
12
9.56
14
13.08
42
15.22
20
20.37
25
20.85
24
21.38
71
21.64
81
21.98
100
27.95
11
28.70
13
35.03
11
Form VIII has the following XRPD °2θ peaks and relative intensities:
°2θ
I/Io
6.82
16
7.35
100
9.79
56
12.70
49
13.00
64
14.70
57
16.04
39
16.78
11
17.08
12
18.11
37
19.43
14
22.27
33
23.07
49
24.33
10
25.50
78
26.54
34
28.62
13
32.09
17
Form IX has the following XRPD °2θ peaks and relative intensities:
°2θ
I/Io
5.28
47
8.21
10
12.66
52
13.81
19
15.02
20
16.32
58
17.78
73
18.70
42
19.74
85
22.22
100
23.80
29
24.86
12
26.33
37
28.52
26
29.86
16
31.92
12
33.21
19
34.67
16
38.15
25
39.54
11
Form X has the following XRPD °2θ peaks and relative intensities:
°2θ
I/Io
8.75
36
9.67
18
10.56
100
11.28
24
13.51
26
14.82
34
15.80
19
16.04
35
16.32
16
17.61
20
18.07
28
19.26
24
20.30
42
20.78
13
21.33
26
21.98
14
22.87
41
24.00
14
24.28
19
26.06
43
26.44
25
26.78
17
27.45
22
27.80
11
28.06
14
28.26
12
30.86
11
38.11
11
and the amorphous form has a single broad peak from 7.28-30.76 XRPD °2θ.
2. A form of hydrocodone bitartrate which is selected from the group consisting of: Form II, Form III, Form IV, Form V, Form VI, Form VII, Form VIII, Form IX, Form X, and an amorphous form, wherein
Form II has XRPD °2θ peaks at 10.39, 17.13, 18.32, 20.86, 21.37, 23.01, 30.24 and 33.55;
Form III has XRPD °2θ peaks at 4.86, 6.74, 8.82, 10.40, 26.76 and 36.40;
Form IV has XRPD °2θ peaks at 7.54, 11.21, 19.21, 22.80 and 25.02;
Form V has XRPD °2θ peaks at 6.57, 12.16, 14.54 and 20.76;
Form VI has XRPD °2θ peaks at 12.54, 12.92, 18.01, 26.15, 28.91, and 32.74;
Form VII has XRPD °2θ peaks at 13.08, 21.64, 21.98 and 28.70;
Form VIII has XRPD °2θ peaks at 7.35, 14.70, 25.50 and 26.54;
Form IX has XRPD °2θ peaks at 8.21, 12.66, 17.78, 19.74, and 22.22;
Form X has XRPD °2θ peaks at 8.75, 10.56, 18.07 and 22.87; and the amorphous form has a single broad peak from 7.28-30.76 XRPD °2θ.
3. A form of claim 1 which is 90-100% pure (wt./wt.).
4. A form of claim 3 that is 95-100% pure.
5. A form of claim 4 that is 98-100% pure.
6. A process to make a Form II of hydrocodone bitartrate of claim 1 , which comprises: dissolving hydrocodone bitartrate in a 9:1 (v/v) water:ethanol mix, filtering the solution, and leaving the mixture uncapped to evaporate to dryness to yield Form II.
7. A process to make a Form III of hydrocodone bitartrate of claim 1 , which comprises: dissolving hydrocodone bitartrate in water, filtering the solution and adding acetone, cooling to 4 degree C. for 4 days then reducing the temperature to minus 20 degrees C. for 1 day and vacuum filtering the solid formed to yield Form III.
8. A process to make a Form IV of hydrocodone bitartrate of claim 1 , which comprises: dissolving hydrocodone bitartrate in water, filtering the solution through a nylon syringe filter, leaving the mixture uncapped to evaporate to dryness, and drying under vacuum to yield Form IV.
9. A process to make a Form V of hydrocodone bitartrate of claim 1 , which comprises: dissolving hydrocodone bitartrate in water, filtering the solution through a nylon syringe filter and adding acetone to the filtrate and then placing mixture in a freezer at minus 20 degrees C. for 5 days and recovering solids by vacuum filtration to yield Form V.
10. A process to make a Form VI of hydrocodone bitartrate of claim 1 , which comprises: dissolving hydrocodone bitartrate in tetrahydrofuran at 60 degrees C., filtering the solution while warm, cooling to room temperature followed by cooling to 4 degrees C. for 3 days followed by cooling to minus 20 degrees C. for 8 days, collecting the solids by vacuum filtration, and drying under vacuum to yield Form VI.
11. A process to make a Form VII of hydrocodone bitartrate of claim 1 , which comprises: dissolving hydrocodone bitartrate in methanol, filtering the solution through a nylon syringe filter, cooling mixture to minus 20 degrees C. for 9 days and removing solids by filtration and then adding ethyl ether to the filtered solution and cooling the resulting mixture to minus 20 degrees C. for 39 days and filtering the solids to yield Form VII.
12. A process to make a Form VIII of hydrocodone bitartrate of claim 1 , which comprises: dissolving hydrocodone bitartrate in acetonitrile, filtering the solution through a nylon syringe filter and leaving the mixture loosely capped to evaporate to dryness to yield Form VIII.
13. A process to make a Form IX of hydrocodone bitartrate of claim 1 , which comprises: dissolving hydrocodone bitartrate in tetrahydrofuran at 60 degrees C., cooling quickly to the temperature of a dry ice acetone mixture and maintaining at a temperature of minus 20 for 26 days, then removing solids through filtration, and leaving uncovered to evaporate to dryness to yield Form IX.
14. A process to make a Form X of hydrocodone bitartrate of claim 1 , which comprises: dissolving hydrocodone bitartrate in acetonitrile, filtering the solution through a nylon syringe filter and leaving the mixture under a foil lid containing 5 pinholes to evaporate to dryness to yield Form X
15. A process to make a form of hydrocodone bitartrate of claim 1 , which comprises: dissolving hydrocodone bitartrate in a 5:1 tetrahydrofuran/water (v/v) mixture, filtering the solution through a nylon syringe filter and leaving the mixture uncapped to evaporate to dryness to yield the amorphous form.
16. A form of hydrocodone bitartrate made by the process of claim 6 .
17. A form of hydrocodone bitartrate made by the process of claim 7 .
18. A form of hydrocodone bitartrate made by the process of claim 8 .
19. A form of hydrocodone bitartrate made by the process of claim 9 .
20. A form of hydrocodone bitartrate made by the process of claim 10 .
21. A form of hydrocodone bitartrate made by the process of claim 11 .
22. A form of hydrocodone bitartrate made by the process of claim 12 .
23. A form of hydrocodone bitartrate made by the process of claim 13 .
24. A form of hydrocodone bitartrate made by the process of claim 14 .
25. A form of hydrocodone bitartrate made by the process of claim 15 .
26. A composition comprising therapeutically effective amounts of one or more of the Forms of claim 1 , optionally in combination with hydrocodone bitartrate, and pharmaceutically acceptable carriers therefor.
27. A method of providing an analgesic effect to a person in need thereof which comprises administering to said person a therapeutic amount of one or more of a Form of claim 1 , optionally in combination with hydrocodone bitartrate.
28. A form of claim 2 which is 90-100 % pure (wt./wt.).
29. A form of claim 28 that is 95-100% pure.
30. A form of claim 29 that is 98-100% pure.